PR Newswire·May 5, 2026, 8:00 PM ET

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology entered a senior secured term loan facility with Avenue Capital Group providing up to $25 million, with an initial $10 million tranche funded at closing.
Additional tranches totaling $15 million are subject to predefined revenue milestones & liquidity conditions.
The company secured approximately $11.5 million in gross proceeds from the immediate exercise of outstanding warrants by a single healthcare-focused institutional investor.
Total financing is intended to support LYMPHIR commercialization, sales force expansion, market access, & general working capital.
Citius will issue warrants to Avenue to purchase up to 11.1 million shares at $0.90 per share, exercisable for five years.
Avenue has the right to convert up to $4 million of the outstanding loan principal into common stock at 120% of the warrant exercise price.
Concurrently, the company issued new unregistered warrants to purchase up to 25.6 million shares at $0.90 per share, expiring five years after stockholder approval.
Existing warrants held by the institutional investor were amended to reduce the exercise price from $1.09 to $0.90 per share.
H.C. Wainwright & Co. served as the exclusive origination, structuring, & placement agent for the financings.
The company plans to file a registration statement with the SEC covering the resale of shares issuable upon exercise of the new warrants.